Established diabetic neuropathy seems irreversible despite improvements in metabolic and vascular risk markers - A retrospective case-control study in a hospital patient cohort

Diabetic Medicine

Volumn 23, Issue 9, 2006, Pages 1016-1020

  Coppini, D V ^a   Spruce, M C ^a   Thomas, P ^a   Masding, M G ^a  

^a POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Diabetic neuropathy; Metabolic factors; Reversibility; Vibration perception threshold

Indexed keywords

BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; COHORT ANALYSIS; DIABETES CONTROL; DIABETIC NEUROPATHY; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; PERCEPTIVE THRESHOLD; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; VIBRATION SENSE;

ADULT; AGED; BIAS (EPIDEMIOLOGY); BIOLOGICAL MARKERS; BLOOD PRESSURE; DIABETIC ANGIOPATHIES; DIABETIC NEUROPATHIES; DISEASE PROGRESSION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPIDS; MALE; MIDDLE AGED; PAIN; PROGNOSIS; SENSORY THRESHOLDS; VIBRATION;

EID: 33747462534     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2006.01934.x     Document Type: Article

References (13)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122: 561-568.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 12 (352): 837-853.
3. Young MJ, Breddy JL, Veves A, Boulton AJM. The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds: a prospective study. Diabetes Care 1994; 17: 557-560.
4. Coppini DV, Wellmer A, Weng C, Young PJ, Anand P, Sonksen PH. The natural history of diabetic peripheral neuropathy determined by a 12 year prospective study using vibration perception thresholds. J Clin Neurosci 2001; 8: 520-524.
5. Vinik AI, Holland MT, Le Beau JM, Liuzzi FJ, Stansberry KB, Colen LB, Diabetic neuropathies. DiabetesCare 1992; 15: 1926-1975.
6. Cappellari I, Airagh L, Ciammola A, Branchi A, Levi Minzi G, Bresolin N. Early peripheral nerve abnormalities in impaired glucose tolerance. Electromyogr Clin Neurophysiol 2005; 45: 241-244.
7. Coppini DV, Sönksen PH. Subclinical peripheral neuropathy may be present at onset of IDDM in high risk patients. Diabetologia 1996; 3 (Suppl. 1): 976.
8. Tesfaye S, Chaturvedi N, Eaton S, Ward JD, Manes C, Ionescu-Tirgoviste C et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352: 341-350.
9. Thrainsdottir S, Malik RA, Dahlin LB, Wiksell P, Eriksson KF, Rosen I et al. Endoneurial capillary abnormalities presage deterioration of glucose tolerance and accompany peripheral neuropathy in man. Diabetes 2003; 52: 2615-2622.
10. Coppini DV, Bowtell PA, Weng C, Sonksen PH. Showing neuropathy is related to increased mortality in diabetic patients - a survival analysis showing an accelerated failure time model. J Clin Epidemiol 2000; 53: 519-523.
11. Wallace P, Guzder R, Coppini DV. VPT - a useful screening tool for vascular disease in diabetes? Diabet Med 2001; 18: 90.
12. Cameron N, Cotter M, Inkster M, Nangle M. Looking to the future: diabetic neuropathy and effects of rosuvastatin on neurovascular function in diabetes models. Diabetes Res Clin Pract 2003; 61: S35-39.
13. Malik RA. Can diabetic neuropathy be prevented by angiotensin-converting enzyme inhibitors. Ann Med 2000; 32: 1-5.